Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 18;14(11):1469.
doi: 10.3390/biom14111469.

Advances in the Regulation of Periostin for Osteoarthritic Cartilage Repair Applications

Affiliations

Advances in the Regulation of Periostin for Osteoarthritic Cartilage Repair Applications

Sunny Y Shih et al. Biomolecules. .

Abstract

Emerging evidence indicates periostin (POSTN) is upregulated in patients with OA, and studies have shown that it can induce the activation of inflammatory cytokines and catabolic enzymes, making it a potential therapeutic target. Link N (LN) is a peptide fragment derived from the link protein and has been demonstrated as an anabolic-like factor and anti-catabolic and anti-inflammatory factors both in vitro and in vivo. This study aims to determine if LN can regulate POSTN expression and function in OA cartilage. Articular cartilage was recovered from donors undergoing total knee replacements to isolate chondrocytes and prepare osteochondral explants. Cells and explants were treated with POSTN and LN (1 and 100 μg) and measured for changes in POSTN expression and various matrix proteins, catabolic and proinflammatory factors, and signaling. To determine the effects of POSTN expression in vivo, a rabbit OA model was used. Immunoprecipitation and in silico modeling were used to determine peptide/POSTN interactions. Western blotting, PCR, and immunohistochemistry demonstrated that LN decreased POSTN expression both in vitro and in vivo. LN was also able to directly inhibit POSTN signaling in OA chondrocytes. In silico docking suggested the direct interaction of LN with POSTN at residues responsible for its oligomerization. Immunoprecipitation experiments confirmed the direct interaction of LN with POSTN and the destabilization of its oligomerization. This study demonstrates the ability of a peptide, LN, to suppress the overexpression and function of POSTN in OA cartilage.

Keywords: Link N; cartilage; chondrocyte; osteoarthritis; periostin.

PubMed Disclaimer

Conflict of interest statement

Two of the authors (J.A. and F.M.) are co-founders of Trepso Therapeutics, Inc., which owns the patent for the use of sLink N, titled “Methods and Compositions for Treatment of Cartilage and Disc Disorders”, as described in PCT patent application No. PCT/CA2014/000656, filed on 4 April 2014. F.M., J.A., P.J.R., L.M.E., and M.P.G. are the inventors of sLink N. The remaining authors have no known competing financial interests or personal relationships that could appear to have influenced the work reported in this paper.

Figures

Figure 1
Figure 1
Increased expression of Postn in human OA cartilage. (A) Immunohistochemical analysis of human OA knee cartilage identified increased cell-associated POSTN in lesional areas when compared to normal cartilage (back arrows). OA knee cartilage, obtained from four donors ranging from 35 to 70 years of age and undergoing total knee arthroplasty, was sectioned and stained for POSTN with Vectastain reagents (Vector Laboratories, Burlingame, CA, USA). (B) Quantitation of periostin positively expressing chondrocytes in superficial and deep cartilage zones. Two-way ANOVA; comparison between normal and OA cartilages; **** p < 0.0001; * p < 0.05; n = 4.
Figure 2
Figure 2
LN suppresses the upregulation of POSTN in human OA osteochondral explants: (a) Human OA osteochondral explants were treated with LN (100 µg/mL) or PBS (CTL) for 14 days. Changes in expression were determined by POSTN staining (arrows); (b) immunohistochemical analysis of POSTN expression in human OA samples, where the stains were divided into three categories: cells unstained with POSTN, cells with minimal Postn staining, and cells with saturated POSTN staining. Means ± SDs; n = 4 donors; chi-squared test.
Figure 3
Figure 3
Effect of LN on POSTN expression in primary human osteoarthritis chondrocytes. (A) Freshly isolated human osteoarthritis (OA) chondrocytes were cultured as micro-pellets and treated for 6 days with LN at 1 µg/mL and 100 µg/mL. Quantitative real-time PCR was used to measure POSTN mRNA expression levels, normalized against GAPDH. (B) Representative western blot analysis showing the effects of the LN treatments (at 1 µg/mL and 100 µg/mL) on POSTN protein levels over a 3-day treatment period. GAPDH was used as the loading control. (C) Densitometric analysis of POSTN protein levels from western blots (panel B), normalized to GAPDH. Statistical significance is indicated as * p < 0.05; ** p < 0.01; and **** p < 0.0001 compared to the untreated control group.
Figure 4
Figure 4
LN suppresses the upregulation of POSTN in a rabbit model of OA. Skeletally mature New Zealand white rabbits underwent unilateral anterior cruciate ligament transection (ACLT) of their left femorotibial joints to induce joint degeneration typical of OA. Beginning at 3 weeks postoperatively, and every three weeks thereafter for 12 weeks, either saline (1 mL) or sLN (100 µg in 1 mL of saline) was injected intraarticularly into the operated knee. Six additional rabbits underwent sham surgery but without ACLT or postoperative injections: (A) POSTN expression, as determined using immunostaining at 12 weeks, was significantly higher in the ACLT rabbits’ knee cartilage when compared with sham knees; (B) the immunohistochemical analysis of the POSTN expression in the rabbit model of OA, where the stains were divided into three categories: cells unstained with POSTN, cells with minimal POSTN staining, and cells with saturated POSTN staining. Statistical significance was assessed using a chi-squared test (p < 0.00001).
Figure 5
Figure 5
LN decreases POSTN signaling in human OA chondrocytes: (A) western blots demonstrating the inhibition of periostin-induced increases in β-catenin (β-Cat) accumulation by LN; (B) densitometry of blots presented in (A). ANOVA; post hoc Dunnett’s test; *** p < 0.0001; n = 3.
Figure 6
Figure 6
LN regulates periostin-induced gene expression in human OA chondrocytes. Chondrocyte pellets were treated with Link N (at 1 or 100 µg/mL) or PBS (CTL) for 6 days in the absence or presence of periostin (20 μg/mL). Gene expression was measured using qPCR. Means ± SDs; n = 3 donors; ANOVA; post hoc Dunnett’s multiple comparison test; **** p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05 in comparison with the control.
Figure 7
Figure 7
LN interacts with POSTN and induces dissociation: (A) The peptide docking of the LN to POSTN (crystal structure: 5yjg) was determined using the CABS–dock web server. The model was created using PyMOL (Schrodinger, LLC). POSTN residues known to be important in its dimerization are shown to interact with LN. (B) The immunoprecipitation (IP) of the LN with POSTN. Biotinylated LN or biotinylated scrambled LN (SC) was attached to Avidin-labelled agarose beads and then incubated with POSTN. Western blotting was performed to identify POSTN–LN interactions. Lane 1: CTL (PBS) with POSTN; lane 2: IP of LN with POSTN; lane 3: SC with POSTN. (C) POSTN incubated with LN dissociates dimer/oligomer formation.

References

    1. Glyn-Jones S., Palmer A.J., Agricola R., Price A.J., Vincent T.L., Weinans H., Carr A.J. Osteoarthritis. Lancet. 2015;386:376–387. doi: 10.1016/S0140-6736(14)60802-3. - DOI - PubMed
    1. Jiang Y. Osteoarthritis year in review 2021: Biology. Osteoarthr. Cartil. 2022;30:207–215. doi: 10.1016/j.joca.2021.11.009. - DOI - PubMed
    1. Jacobs C.A., Keller L.E., Zhang S., Fu Q., Hunt E.R., Stone A.V., Conley C.E.W., Lattermann C., Fortier L.A. Periostin regulation and cartilage degradation early after anterior cruciate ligament reconstruction. Inflamm. Res. 2023;72:387–394. doi: 10.1007/s00011-022-01678-9. - DOI - PubMed
    1. Attur M., Krasnokutsky-Samuels S., Samuels J., Abramson S.B. Prognostic biomarkers in osteoarthritis. Curr. Opin. Rheumatol. 2013;25:136–144. doi: 10.1097/BOR.0b013e32835a9381. - DOI - PMC - PubMed
    1. Sonnenberg-Riethmacher E., Miehe M., Riethmacher D. Periostin in Allergy and Inflammation. Front. Immunol. 2021;12:722170. doi: 10.3389/fimmu.2021.722170. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources